There’s a new twist in the recent uproar about how pharmaceutical companies are spiking costs for variations of medicines that have been around for decades. Little children often have a difficult time swallowing pills. Pharmacists can make liquid versions, but there’s a risk of an adverse reaction to these ad hoc versions. So it figures that standardized liquid forms of older medications would find a market.
Unfortunately, insurers may have a difficult time swallowing the prices. Lisinopril and enalapril are ACE inhibitors that can be used to treat hypertension in children, a relatively rare condition. But the liquid formulation of lisinopril, Qbrelis, is priced 775 times higher than the generic tablet, and the liquid formulation of enalapril, Epaned, is priced 121 times higher than the generic tablet. Both formulations are made by Silvergate Pharmaceuticals in suburban Denver.